These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12056922)

  • 21. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
    Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
    Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
    Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
    Chue PS; Heeg B; Buskens E; van Hout BA
    Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.
    Werneck AP; Hallak JC; Nakano E; Elkis H
    Psychiatry Res; 2011 Aug; 188(3):315-9. PubMed ID: 21596442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
    Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
    Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
    Csernansky JG; Mahmoud R; Brenner R;
    N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management strategies for the treatment of schizophrenia.
    Kane JM
    J Clin Psychiatry; 1999; 60 Suppl 12():13-7. PubMed ID: 10372604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
    Taipale H; Tanskanen A; Correll CU; Tiihonen J
    Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.
    Mortimer A; Williams P; Meddis D
    J Int Med Res; 2003; 31(3):188-96. PubMed ID: 12870371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.